Moreover, certain studies have suggested that liver function tests themselves, including ALT, AST, gamma-glutamyltransferase (GGT), and alkaline phosphatase (ALP), can be potential CVD risk markers, independent of their relationship to NAFLD [27,28,29]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.